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ABSTRACT
An open-label randomised clinical trial was designed to compare the efficacy and tolerance of
levofloxacin and ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients
with high-risk neutropenia, and to monitor the emergence of antimicrobial resistance. Adult patients
(n = 242) scheduled to receive intensive treatment for haematological malignancies were assigned
randomly to receive oral prophylaxis with either levofloxacin 500 mg once-daily (n = 122), or
ciprofloxacin 500 mg twice-daily plus phenethicillin 250 mg four-times-daily (n = 120). The primary
endpoint was failure of prophylaxis, defined as the first occurrence of either the need to change the
prophylactic regimen or the initiation of intravenous broad-spectrum antibiotics. This endpoint was
observed in 89 (73.0%) of 122 levofloxacin recipients and in 85 (70.8%) of 120 ciprofloxacin plus
phenethicillin recipients (RR 1.03, 95% CI 0.88–1.21, p 0.71). No differences were noted between the two
groups with respect to secondary outcome measures, including time to endpoint, occurrence of fever,
type and number of microbiologically documented infections, and administration of intravenous
antibiotics. A questionnaire revealed that levofloxacin was tolerated significantly better than cipro-
floxacin plus phenethicillin. Surveillance cultures indicated the emergence of viridans group (VG)
streptococci resistant to levofloxacin in 17 (14%) of 122 levofloxacin recipients; in these cases, the
prophylactic regimen was adjusted. No bacteraemia with VG streptococci occurred. It was concluded
that levofloxacin and ciprofloxacin plus phenethicillin are equally effective in the prevention of bacterial
infections in neutropenic patients, but that levofloxacin is tolerated better. Emergence of levofloxacin-
resistant VG streptococci is of concern, but appears to be a manageable problem.
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INTRODUCTION
Quinolones have been used extensively in the
past two decades for the prevention of bacterial
infections during neutropenia in cancer patients.
It is evident that this approach reduces the
incidence of Gram-negative bacteraemia signifi-
cantly [1–3]. Unfortunately, this is counterbal-
anced by an increased incidence of infections with
Gram-positive bacteria. In particular, viridans
group (VG) streptococci and coagulase-negative
staphylococci have emerged as a frequent cause
of morbidity and mortality [4,5]. To overcome this
problem, quinolone prophylaxis has been com-
bined with other antimicrobial agents, e.g., peni-
cillin, macrolides and vancomycin, that are active
against Gram-positive cocci [6–9].
An alternative approach could involve the use
of new-generation quinolones, which are more
potent against Gram-positive pathogens. Levo-
floxacin, as a representative of this group, has
been reported to reduce the incidence of fever and
other infection-related outcomes in neutropenic
cancer patients, compared with a placebo
[2,10,11], but important issues remain to be
addressed. First, no data are available from
controlled clinical trials that allow a direct
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comparison between the use of levofloxacin
prophylaxis and the use of ciprofloxacin plus an
antibiotic with anti-Gram-positive bacteria activity.
Second, there have been some alarming reports
concerning the emergence of levofloxacin-resist-
ant Gram-positive microorganisms, in particular
VG streptococci [12,13].
During the past few years, patients admitted to
the haematology department of the VU Univer-
sity Medical Center, Amsterdam, The Nether-
lands have received ciprofloxacin plus
phenethicillin for the prevention of bacterial
infections during neutropenia as the standard of
care. When levofloxacin became available in The
Netherlands, the randomised clinical trial des-
cribed in this study was conducted to compare
levofloxacin with ciprofloxacin plus phenethicillin
with respect to their efficacy as antibacterial
prophylaxis for neutropenic patients. In addition,
the trial was designed to investigate the tolerance
of these compounds and to closely monitor
emerging antimicrobial resistance.
PATIENTS AND METHODS
Patients
Consecutive adult patients with a haematological malignancy
who were hospitalised at the haematology department of the
VU University Medical Center for high-dose combination
chemotherapy, with or without autologous or allogeneic
haematopoietic stem-cell transplantation, were eligible for this
study. An anticipated granulocytopenic period (granulocytes
<0.5 · 109 ⁄L) of ‡10 days was required. Patients were enrolled
only once. Exclusion criteria were active infection or antibac-
terial therapy at entry, a history of hypersensitivity to
fluoroquinolones, a creatinine clearance of <15 mL ⁄min, or
elevation of transaminases to greater than three-fold the
normal upper limit. The protocol was approved by the
institutional scientific and ethical committees, and all partici-
pants provided written informed consent.
Randomisation and prophylactic regimen
The study was a prospective, single-centre, open-label, rand-
omised clinical trial. Patients were assigned randomly by
consecutively drawn, sealed envelopes to receive either levo-
floxacin 500-mg tablets once-daily or ciprofloxacin 500-mg
tablets twice-daily, plus, from day 7 after the start of
chemotherapy, phenethicillin 250-mg tablets four-times-daily.
Prophylaxis was begun on the first day of chemotherapy and
was continued until recovery to a granulocyte count of
>0.5 · 109 ⁄L. Phenethicillin was initiated on day 7 because,
from that time on, oropharyngeal mucositis was to be expected,
and this has been identified as an independent risk-factor for
infections with streptococci [4]. Compliance was monitored by
counting tablets. In addition to the study medication, all
patients received fluconazole 50 mg once-daily and 2 mg nasal
amphotericin B spray three-times-daily. A central venous
catheter was inserted before the start of chemotherapy.
Clinical and microbiological evaluation of subjects
Randomised patients were examined daily for clinical signs of
infection. Surveillance cultures for identification of colonising
bacteria and yeasts were taken from throat and anus before the
first dose of the study drugs and once-weekly thereafter. If
appropriate, the prophylactic regimen was adjusted according
to the resistance patterns of the microorganisms identified.
If the axillary temperature increased to >38.5C, or if other
signs or symptoms of an infection occurred without fever,
clinical evaluation took place according to a local protocol,
including a complete physical examination, a chest X-ray, and
appropriate samples for microbiological cultures. At least two
separate blood samples were obtained for culture, from both
the central venous catheter and from a peripheral vein.
Subsequently, empirical antibiotic therapy was initiated, con-
sisting of intravenous imipenem–cilastatin 500 mg four-times-
daily. If the fever did not resolve in £96 h, patients received
antifungal therapy. In case of initiation of broad-spectrum
antibacterial therapy, levofloxacin or ciprofloxacin were con-
tinued, but phenethicillin was discontinued.
Pathogenic microorganisms, isolated either from surveil-
lance cultures or from cultures obtained from patients with
presumed infection, were identified to the species level by
standard microbiological techniques. MICs of levofloxacin and
ciprofloxacin for staphylococci, streptococci and Gram-negat-
ive bacilli were determined by Etests (AB Biodisk, Solna,
Sweden). Susceptibility of streptococci to phenethicillin was
determined by disk-diffusion tests and was reported as
susceptible, intermediately-resistant or resistant. Breakpoints
were defined according to CLSI standards.
Tolerance of the study medication and toxicity
Patients were asked to complete a questionnaire, which recor-
ded a ‘tolerance score’ for the studymedication on a daily basis.
Tolerance of the studydrugwas classified as ‘not able to take the
study drug’, ‘difficult intake’, ‘minor problems on intake’, or
‘intake without any problem’. Any adverse event that was
possibly or probably related to the study medication was
recorded. Routine clinical chemistry tests were performed
weekly, and any deterioration in liver enzymes, bilirubin or
kidney function was recorded. All adverse events were classi-
fied using the Common Terminology Criteria for Adverse
Events v.3.0 (CTCAE; National Cancer Institute, Bethesda, MD,
USA). Following an adverse event, studymedication was either
continued or discontinued, according to the judgement of the
responsible physician.
Outcome
The primary outcome measure of the study was success or
failure of the prophylactic regimen. Failure of prophylaxis was
a composite endpoint, defined as the need to change the
prophylactic regimen for any reason, or the initiation of broad-
spectrum antibacterial therapy, whichever event occurred first.
The primary endpoint was chosen to reflect the effects of the
prophylactic regimens on the most relevant clinical events.
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Furthermore, the study was designed to include patient follow-
up beyond this first event, and data were analysed on an
intention-to-treat basis. Secondary outcome measures were the
time to primary endpoint, the occurrence of fever, the type and
number of documented infections, the use of antimicrobial
agents, and the tolerance of the study drug. Moreover, the
study design provided close monitoring of the acquisition of
antimicrobial resistance by the pathogens isolated.
Statistical evaluation
It was estimated from previous studies in the same ward
that c. 30% of patients survive the neutropenic episode
without requiring change of prophylaxis or initiation of
broad-spectrum antibiotics. Thus, according to the defini-
tions used in the present study, 70% of patients were
expected to experience failure of prophylaxis. Sample size
was calculated to detect a 25% reduction (from 70% to
52%) in failure of prophylaxis. To detect such a difference
with a significance level (a) of 0.05 (two-tailed) and a
statistical power of 80%, 120 patients per arm were
required. Differences between groups in categorical varia-
bles were analysed with the chi-square test. In case of
variables with an ordering or grading scale, the chi-square
test for trend was used. The relative differences between
the groups were also expressed as relative risks (RRs) with
95% CIs. The Mann–Whitney non-parametric U-test was
used for comparison of means. Differences in survival
without failure of prophylaxis were assessed by the log-
rank test, and Kaplan–Meier curves were plotted for each
study group.
RESULTS
Between January 2002 and July 2005, 245 patients
were enrolled in the study. Three patients were
excluded from analysis. One patient withdrew
informed consent, another patient was errone-
ously enrolled twice, and one patient died on the
day of randomisation because of disease pro-
gression. Of the 242 evaluable patients, 122 were
assigned to receive levofloxacin and 120 to
receive ciprofloxacin and phenethicillin. Basic
patient characteristics of the two treatment
groups are listed in Table 1. No significant
differences were found in gender, age, type
and remission status of the haematological dis-
ease and treatment variables, including stem-cell
transplantation procedures. However, the neu-
tropenic episode was significantly longer in the
ciprofloxacin–phenethicillin group (mean differ-
ence to a granulocyte count of >0.5 ·
109 ⁄L = 1.4 days, p 0.044; mean difference to
granulocyte count >0.1 · 109 ⁄L = 1.6 days,
p 0.017). Patients receiving levofloxacin
remained in hospital for a mean of 25.5 days,
compared with 28.1 days for patients receiving
ciprofloxacin–phenethicillin, but this was not
statistically significant (mean difference 2.6 days,
p 0.13).
Failure of prophylaxis and febrile episodes
The primary endpoint ‘failure of prophylaxis’ was
observed in 89 (73.0%) of 122 patients receiving
levofloxacin, compared with 85 (70.8%) of 120
patients receiving ciprofloxacin–phenethicillin
(RR 1.03, 95% CI 0.88–1.21, p 0.71). The distribu-
tion of events responsible for failure of prophy-
laxis, change of the prophylactic regimen and
initiation of intravenous antibiotics were similar
in the two groups. The time to failure of prophy-
laxis, and Kaplan–Meier estimates of the propor-
tion of patients surviving without failure of
prophylaxis, showed no clear advantage for either
prophylactic regimen.
In the intention-to-treat analysis, 28 (23.0%) of
122 patients in the levofloxacin group needed
adjustment of the prophylactic regimen during
the study period, compared with 39 (32.5%) of
120 patients in the ciprofloxacin–phenethicillin
group (RR 0.71, 95% CI 0.47–1.07, p 0.07). The
main reason for change of prophylaxis in the
levofloxacin group was decreased susceptibility
or resistance of bacterial isolates, as indicated by
surveillance culture data. Intolerance of the study
medication was the most common reason for
change of the prophylactic regimen in patients
receiving ciprofloxacin–phenethicillin. This event
occurred significantly less frequently in levofl-
oxacin recipients (RR 0.11, 95% CI 0.03–0.46,
p 0.0002).
Table 1. Characteristics of patients included in the study
Levofloxacin Ciprofloxacin
n % n %
Total patients 122 50.4 120 49.6
Age, median, years (range) 55 (18–71) 54 (19–71)
Gender
Male 76 62.3 79 65.8
Female 46 37.7 41 34.2
Diagnosis
ALL 10 8.2 10 8.3
AML 19 15.6 28 23.3
Multiple myeloma 46 37.7 39 32.5
Lymphoma 35 28.7 34 28.4
Myelodysplasia 4 3.3 3 2.5
Other 8 6.5 6 5.0
Stem-cell transplantation 86 70.5 78 65.0
Autologous stem cells 74 86.0 65 83.3
Allogeneic stem cells 12 14.0 13 16.7
All differences not significant.
ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia.
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The occurrence and duration of fever, and the
number of patients receiving broad-spectrum
intravenous antibiotics, were similar in both
groups. Furthermore, there were no significant
differences in either type or number of antibac-
terial and antifungal antibiotics administered. The
number of days (mean ± SD) for which patients
received intravenous antibiotics was 9.2 ± 7.1 in
the levofloxacin group compared with 10.9 ± 7.4
in the ciprofloxacin–phenethicillin group. The
difference of 1.7 days in favour of the levofloxacin
group almost reached statistical significance
(p 0.051).
Infections
The number of microbiologically documented
infections was similar in both groups, with
21 (17.2%) of such infections observed in
levofloxacin recipients and 22 (18.3%) in
ciprofloxacin–phenethicillin recipients (RR 0.94,
95% CI 0.55–1.62, p 0.82). Most patients with a
microbiologically documented infection had bac-
teraemia, with a predominance of single Gram-
positive microorganisms. Bacteraemia with
Gram-negative microorganisms was a rare event
and occurred in only two patients receiving
levofloxacin (one patient with a single Gram-
negative organism and one with polymicrobial
bacteraemia), and was not observed among
patients receiving ciprofloxacin-–phenethicillin.
Clinically documented infections encompassed
predominantly pulmonary infiltrates on the
chest X-ray, and mouth or throat ulcera-
tions. These infections were observed in 12
(9.8%) levofloxacin recipients and in 18 (15.0%)
ciprofloxacin–phenethicillin recipients (RR 0.66,
95% CI 0.33–1.30, p 0.22). Fever of unknown
origin occurred in 40 (32.8%) levofloxacin recip-
ients and in 29 (24.2%) ciprofloxacin–phenethi-
cillin recipients (RR 1.36, 95% CI 0.90–2.04,
p 0.13).
Microbiological evaluations
Throat surveillance cultures (levofloxacin,
n = 448; ciprofloxacin–phenethicillin, n = 485)
yielded predominantly VG streptococci (Table 2).
From day 1 to day 4, VG streptococci were found
in 111 (91%) of 122 patients in the levofloxacin
group, compared with 108 (90%) of 120 patients
in the ciprofloxacin–phenethicillin group. During
the subsequent study period, the number of
patients with throat surveillance cultures that
yielded VG streptococci decreased in both
groups. However, the colonisation rate of VG
streptococci was reduced faster and to a larger
extent over time in the levofloxacin group com-
pared with the ciprofloxacin–phenethicillin group
(chi-square for trend, p <0.0001). From day 1 to
day 4, 107 (96%) of 111 VG streptococcal isolates
from levofloxacin recipients were susceptible to
levofloxacin, two (2%) were resistant and two
(2%) were intermediately-susceptible. In contrast,
only 25 (23%) of 108 VG streptococcal isolates
from ciprofloxacin–phenethicillin recipients were
susceptible to ciprofloxacin, 12 (11%) were resis-
tant and 71 (66%) were intermediately-susceptible.
VG streptococci resistant to phenethicillin were
not isolated from patients receiving ciprofloxacin–
phenethicillin prophylaxis, although isolates from
30 patients had intermediate susceptibility. Anal
surveillance cultures (levofloxacin, n = 469;
ciprofloxacin–phenethicillin, n = 503) yielded
predominantly Escherichia coli and other Entero-
bacteriaceae. Eradication of these microorganisms
was highly efficient with both prophylactic regi-
mens. At baseline, two patients in each group had
Table 2. Pathogens isolated and their resistance patterns
No. of patients with isolate
Levofloxacin Ciprofloxacin
Total Resistant Total Resistant
Surveillance cultures
Gram-positive microorganisms
VG streptococci, at baseline 111 2 108 12
VG streptococci, from day 4 67 17 101 51
b-Haemolytic streptococci, at baseline 12 0 16 0
b-Haemolytic streptococci, from day 4 2 0 1 0
Staphylococcus aureus, at baseline 7 0 6 0
S. aureus, from day 4 0 0 1 0
Gram-negative microorganisms
Escherichia coli, at baseline 81 2 79 2
E. coli, from day 4 12 3 7 4
Other Enterobacteriaceae, at baseline 40 0 42 0
Other Enterobacteriaceae, from day 4 5 0 3 0
Pseudomonas aeruginosa 1 0 2 0
Bacterial isolates
Blood
Coagulase-negative staphylococci 18 18 21 21
Enterococci 5 5 6 6
VG streptococci 0 0 2 2
S. aureus 0 0 1 1
Stenotrophomonas maltophilia 1 1 0 0
Serratia marcescens 1 0 0 0
Sputum or bronchoalveolar lavage fluid
Sten. maltophilia 2 1 0 0
Legionella pneumophila 0 0 1 1
Other sites
Enterococci 3 2 2 1
VG, viridans group.
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quinolone-resistant E. coli. Acquired resistance in
E. coli during the study period was observed for
one patient receiving levofloxacin, and for two
patients receiving ciprofloxacin–phenethicillin.
Most bacterial isolates from blood cultures and
from cultures of other sites were resistant to
levofloxacin and ciprofloxacin (Table 2). The
number and type of bacteria isolated were similar
in both groups, with coagulase-negative staphy-
lococci and enterococci identified most fre-
quently.
Tolerance of study drug and adverse events
The questionnaire concerning daily tolerance of
the study medication was completed by 100
patients receiving levofloxacin (response rate
82%) and by 79 patients receiving ciprofloxacin–
phenethicillin (response rate 66%). From day 4,
the mean tolerance score per day was significantly
lower for ciprofloxacin–phenethicillin recipients
than for patients receiving levofloxacin (p <0.05),
indicating that patients considered the intake of
levofloxacin less problematic than that of cipro-
floxacin–phenethicillin.
Biochemistry values, expressed as maximum
CTCAE toxicity grade of transaminases, creati-
nine and albumin levels, were similar for the two
groups, both at baseline and during the study
period. In addition, adverse events were docu-
mented at the same frequency in the two treat-
ment groups. Skin rash was observed most
frequently, occurring in 16 (13.1%) levofloxacin
recipients and 15 (12.5%) ciprofloxacin–pheneth-
icillin recipients (RR 1.05, 95% CI 0.54–2.03,
p 0.89).
Mortality
The overall mortality rate was 2.5% (six of 242
patients). Two patients in the levofloxacin group
died, one from sinusoidal obstruction syndrome
of the liver, and the other from respiratory failure
caused by a pulmonary infection, with no caus-
ative microorganism identified. Four patients
died in the ciprofloxacin–phenethicillin group,
one from a probable infection with Aspergillus
fumigatus, a second from cardiac arrest, and two
from respiratory failure. Of the last two patients,
the alveolar lavage fluid from one patient yielded
flavobacteria and Candida albicans, while cultures
remained negative for the other patient.
DISCUSSION
The results of this randomised controlled clinical
trial demonstrate that levofloxacin and cipro-
floxacin plus phenethicillin are equally success-
ful as antibacterial prophylaxis for neutropenic
patients with haematological malignancies. Fail-
ure of prophylaxis, as the primary outcome
measure, was observed at the same frequency in
the two treatment groups, as were its composites:
the initiation of broad-spectrum antibacterial
antibiotics, and the need for change of the
prophylactic regimen. Other infection-related out-
comes, e.g., the time to failure of prophylaxis,
occurrence of fever, the number of patients with a
microbiologically documented infection, and the
number of patients who received broad-spectrum
intravenous antibiotics, did not favour either of
the prophylactic strategies. However, patients
receiving ciprofloxacin–phenethicillin had a dis-
crete, but significantly longer, duration of neu-
tropenia of c. 1.6 days. This finding probably
accounts for the trend towards a longer duration
of hospital stay for these patients, and may be an
explanation for the (almost significant) higher
number of days for which patients in the cipro-
floxacin–phenethicillin group needed intravenous
antibiotics. It is well-known that prolonged
administration of b-lactam antibiotics may induce
neutropenia, probably because of a direct toxic
effect on the bone marrow or an immune-medi-
ated effect [14,15]. Considering the fact that
duration of neutropenia has been identified as
an independent risk-factor for the occurrence and
severity of infections, and as a critical factor in a
successful outcome, this finding may be of clinical
importance [16,17].
It was assumed that patients receiving one
tablet of levofloxacin per day would tolerate the
study medication better than patients receiving
two tablets of ciprofloxacin plus four tablets of
phenethicillin. The results of the questionnaire
confirmed this supposition. From day 4, the mean
tolerance score for levofloxacin was significantly
higher than the score for ciprofloxacin–pheneth-
icillin. In line with these results, a change of
prophylaxis because of intolerance of the study
drugs was necessary for significantly more
patients receiving ciprofloxacin–phenethicillin
than for those receiving levofloxacin. Since these
patients are commonly suffering from discom-
forting nausea and mucositis, a better tolerance of
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prophylactic medication is important and may
improve therapy compliance. However, the
results of the questionnaire need to be interpreted
with caution. The response rate was 82% in
the levofloxacin group and 66% in the ciprofl-
oxacin–phenethicillin group, which may indicate
selection bias. Patients were sometimes disap-
pointed not to have been assigned to receive
levofloxacin, and other patients became very ill
during the study period. It is possible that these
patients, in particular, were less motivated or less
able to complete and return the questionnaire.
The prophylactic administration of both cipro-
floxacin–phenethicillin and levofloxacin resulted
in good control over Gram-negative bacteria, and
only two patients, both receiving levofloxacin,
developed Gram-negative bacteraemia. The effic-
acy of quinolone prophylaxis in reducing Gram-
negative infections has been well-documented,
although the emergence of quinolone-resistant
bacteria, particularly E. coli, has been reported
[18,19]. Moreover, prophylaxis with the older-
generation quinolones, e.g., ciprofloxacin, has
been associated with an increase in the number
of Gram-positive infections. Levofloxacin and
other newer quinolones have enhanced activity
against Gram-positive microorganisms, and may
potentially overcome this problem. However,
early reports concerning levofloxacin adminis-
tered as antibacterial prophylaxis suggest that its
use may be associated with the selection of
quinolone-resistant VG streptococci [12,13]. This
is a major drawback, as these microorganisms
have been reported to be responsible for up to
39% of cases of bacteraemia in neutropenic
patients, and may result in serious complications,
including endocarditis, adult respiratory distress
syndrome, shock and even death [4,13,20]. In the
present study, surveillance cultures yielded levo-
floxacin-resistant VG streptococci from 17 (14%)
of 122 levofloxacin recipients. In these patients the
prophylactic regimen was adjusted, in most
instances by the addition of penicillin. This
proved to be a valuable approach, as no bacter-
aemia with VG streptococci occurred in the
levofloxacin group. However, in agreement with
data published previously, the bacteria isolated
most frequently from patients with a bloodstream
infection were coagulase-negative staphylococci
and enterococci [20,21]. As expected, these bac-
teria were invariably resistant to levofloxacin and
ciprofloxacin. This finding should be taken into
account in the choice of empirical antibiotic
therapy, and underscores the importance of meti-
culous care of central venous access devices.
In conclusion, levofloxacin was as efficacious as
ciprofloxacin plus phenethicillin for the preven-
tion of bacterial infections in neutropenic patients
with cancer. However, levofloxacin is better-tol-
erated, which may benefit compliance with ther-
apy. Resistance in VG streptococci does occur, but
this problem appears to be manageable if resist-
ance patterns are monitored closely. The present
study does not answer the question as to which
patients with neutropenia benefit most from the
prophylactic administration of levofloxacin and
other quinolones, and nor does it support the
unlimited or uncontrolled use of these agents. As
outlined in the guidelines published by the
Infectious Diseases Society of America [22], rout-
ine quinolone prophylaxis for all neutropenic
patients is not recommended. Based on the
estimated infection risk for their own category
of neutropenic patients, and with careful consid-
eration of local antimicrobial resistance patterns,
physicians should weigh the benefits of quinolone
prophylaxis against the potential dangers of this
approach.
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